Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.55 |
| ▸ | NAMPT | P43490 | 4/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SPTLC2 | O15270 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14258005 | 0.92 | P2RX7 (0.60) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14258021 | 0.90 | P2RX7 (0.57) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14257977 | 0.90 | P2RX7 (0.57) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14257967 | 0.90 | P2RX7 (0.57) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14257991 | 0.89 | P2RX7 (0.56) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14257956 | 0.89 | P2RX7 (0.60) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14258011 | 0.89 | P2RX7 (0.55) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14257989 | 0.87 | P2RX7 (0.60) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14257982 | 0.87 | P2RX7 (0.55) | P2RX7NAMPTROCK2KDM4EALDH1A1 | |
| SCHEMBL14257958 | 0.86 | ALDH1A1 (0.58) | P2RX7NAMPTROCK2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885NAMPT 641/4885ROCK2 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.